{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:19:01Z","timestamp":1790054341481,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703592"],"award-info":[{"award-number":["81703592"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Natural Science Foundation-Department Joint Fund","award":["2023JJ60382"],"award-info":[{"award-number":["2023JJ60382"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Doxorubicin has become the first-line antitumor drug clinically, but severely limited by multiple side effects, especially cardiotoxicity. Liposomal doxorubicin therefore replaced traditional doxorubicin for low toxicity and high efficiency. Previous studies have suggested liver and kidney may be the main organs affected by liposomal doxorubicin. Due to insufficient clinical evidence, we set out to analyze the effect of liposomal doxorubicin on liver and renal function in breast cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Our retrospective analysis included breast cancer patients aged 30\u201370\u00a0years old who were assigned to two groups based on liposomal doxorubicin intake. We evaluated changes in liver and renal function. Multivariate logistic regression model was used to assess the risk factors of liver function damage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ultimately, 631 patients for liver function analysis cohort and 611 cases for renal function analysis cohort. Patients receiving liposomal doxorubicin had significantly higher liver function damage rate compared to control group (52.20% vs 9.82%, p\u00a0&amp;lt;\u00a00.001), but there was no difference in the incidence of renal damage events between the two groups. Multivariate analysis shows total doses divided by body surface area is a significant, independent risk factor for liver function damage (odds ratio 1.005 [1.002\u20131.018], p\u00a0&amp;lt;\u00a00.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Liposomal doxorubicin treatment is associated with higher liver function damage in breast cancer patients, but has no effect on renal function. Together with risk factor analysis, our study underlines the importance to pay attention for patient\u2019s age before taking liposomal doxorubicin, alongside liver function after the first and long-term treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/toxres\/tfad072","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:26:52Z","timestamp":1693204012000},"page":"807-813","source":"Crossref","is-referenced-by-count":5,"title":["Clinical observation of liposomal doxorubicin on liver and renal function in patients with breast cancer"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-5415","authenticated-orcid":false,"given":"Mingliang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, The Third Hospital of Changsha , No. 176, Labor West Road, Tianxin District, Changsha, Hunan 410035 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-3250","authenticated-orcid":false,"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University , No. 87, Xiangya Road, Kaifu District, Changsha, Hunan 410008 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-7852","authenticated-orcid":false,"given":"Jie","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University , No. 87, Xiangya Road, Kaifu District, Changsha, Hunan 410008 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"3","key":"2023103102463053400_ref1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"2023103102463053400_ref2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lfs.2017.05.003","article-title":"Polyphenols, autophagy and doxorubicin-induced cardiotoxicity","volume":"180","author":"Shabalala","year":"2017","journal-title":"Life Sci"},{"issue":"4","key":"2023103102463053400_ref3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.114.093849","article-title":"Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A","volume":"86","author":"Hanna","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2023103102463053400_ref4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/cgt.2017.9","article-title":"The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials","volume":"24","author":"Ansari","year":"2017","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2023103102463053400_ref5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejca.2014.11.017","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"51","author":"Mahner","year":"2015","journal-title":"Eur J Cancer"},{"issue":"9","key":"2023103102463053400_ref6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/1061186X.2016.1172591","article-title":"Liposomal doxorubicin: the good, the bad and the not-so-ugly","volume":"24","author":"Szebeni","year":"2016","journal-title":"J Drug Target"},{"issue":"6","key":"2023103102463053400_ref7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0960327115597468","article-title":"Beneficial effects of carnosine and carnosine plus vitamin E treatments on doxorubicin-induced oxidative stress and cardiac, hepatic, and renal toxicity in rats","volume":"35","author":"Kumral","year":"2016","journal-title":"Hum Exp Toxicol"},{"issue":"28","key":"2023103102463053400_ref8","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2023103102463053400_ref9","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci Rep"},{"issue":"19","key":"2023103102463053400_ref10","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.2015.65.3329","article-title":"Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish Group for Research on sarcoma study","volume":"34","author":"Martin-Broto","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023103102463053400_ref11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.yexmp.2017.03.005","article-title":"Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats","volume":"102","author":"Jacevic","year":"2017","journal-title":"Exp Mol Pathol"},{"issue":"8","key":"2023103102463053400_ref12","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3390\/ijms19082370","article-title":"The efficacy of Amifostine against multiple-dose doxorubicin-induced toxicity in rats","volume":"19","author":"Ja\u0107evi\u0107","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2023103102463053400_ref13","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1016\/j.sjbs.2021.04.030","article-title":"Protective effect of diosmin against doxorubicin-induced nephrotoxicity","volume":"28","author":"Ali","year":"2021","journal-title":"Saudi J Biol Sci"},{"issue":"5","key":"2023103102463053400_ref14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s10637-014-0111-8","article-title":"Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the eastern cooperative oncology group","volume":"32","author":"Ciombor","year":"2014","journal-title":"Investig New Drugs"},{"issue":"4","key":"2023103102463053400_ref15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2023103102463053400_ref16","first-page":"273","article-title":"Protective effect of pravastatin on doxorubicin-induced hepatotoxicity","volume":"118","author":"Mansouri","year":"2017","journal-title":"Bratisl Lek Listy"},{"issue":"9","key":"2023103102463053400_ref17","doi-asserted-by":"crossref","first-page":"e21940","DOI":"10.1002\/jbt.21940","article-title":"Alpha lipoic acid prevents doxorubicin-induced nephrotoxicity by mitigation of oxidative stress, inflammation, and apoptosis in rats","volume":"31","author":"el-Sayed","year":"2017","journal-title":"J Biochem Mol Toxicol"},{"issue":"3 Suppl 1","key":"2023103102463053400_ref18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/abd1806-4841.20153708","article-title":"Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin","volume":"90","author":"Ma","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"6","key":"2023103102463053400_ref19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.1991.476","article-title":"Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin","volume":"64","author":"Gabizon","year":"1991","journal-title":"Br J Cancer"},{"issue":"13","key":"2023103102463053400_ref20","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-06-0226","article-title":"Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors","volume":"12","author":"Hauck","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2023103102463053400_ref21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2017.08.030","article-title":"Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation","volume":"264","author":"Alibolandi","year":"2017","journal-title":"J Control Release"},{"issue":"4","key":"2023103102463053400_ref22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ijc.28083","article-title":"A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma","volume":"133","author":"Thornton","year":"2013","journal-title":"Int J Cancer"},{"issue":"7","key":"2023103102463053400_ref23","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1177\/1078155218798157","article-title":"Renal toxicity with liposomal doxorubicin in metastatic breast cancer","volume":"25","author":"Yemm","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2023103102463053400_ref24","first-page":"44","article-title":"Consensus opinion on analysis and monitoring of liver biochemical tests (draft)","volume":"S-10","author":"Chinese Medical Association Liver Diseases Branch, and Chinese Medical Association Digestive Diseases Branch","year":"2009","journal-title":"Chinese Medical Association"},{"issue":"10","key":"2023103102463053400_ref25","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2023103102463053400_ref26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023103102463053400_ref27","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2023103102463053400_ref28","first-page":"28","article-title":"Guideline for screening, diagnosis, prevention and treatment of chronic kidney disease","volume":"37","author":"Expert Group on Early Detection","year":"2017","journal-title":"Chin J Practic Intern Med"},{"issue":"2","key":"2023103102463053400_ref29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2023103102463053400_ref30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2023103102463053400_ref31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCRESAHA.110.224519","article-title":"Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers","volume":"108","author":"Chen","year":"2011","journal-title":"Circ Res"},{"issue":"14","key":"2023103102463053400_ref32","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1080\/14656566.2022.2124107","article-title":"Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients","volume":"23","author":"Stansfeld","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2023103102463053400_ref33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.amjcard.2020.03.040","article-title":"Myocardial 2D strain during long-term (&gt;5 years) follow-up of childhood survivors of acute lymphoblastic leukemia treated with anthracyclines","volume":"127","author":"Pourier","year":"2020","journal-title":"Am J Cardiol"},{"issue":"5","key":"2023103102463053400_ref34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2023103102463053400_ref35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jat.3499","article-title":"Review of the effects of manufactured nanoparticles on mammalian target organs","volume":"38","author":"Wu","year":"2018","journal-title":"J Appl Toxicol"},{"issue":"9","key":"2023103102463053400_ref36","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s13346-022-01147-0","article-title":"Three-dimensional (3D) liver cell models\u2014a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials","volume":"12","author":"Tutty","year":"2022","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"2023103102463053400_ref37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/bdd.2063","article-title":"Prediction of liver volume\u2014a population-based approach to meta-analysis of paediatric, adult and geriatric populations\u2014an update","volume":"38","author":"Small","year":"2017","journal-title":"Biopharm Drug Dispos"},{"issue":"8\u20139","key":"2023103102463053400_ref38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.exger.2005.06.009","article-title":"Age-related changes in liver structure and function: implications for disease?","volume":"40","author":"Schmucker","year":"2005","journal-title":"Exp Gerontol"},{"issue":"12","key":"2023103102463053400_ref39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40266-015-0318-1","article-title":"Age-related changes in hepatic function: an update on implications for drug therapy","volume":"32","author":"Tan","year":"2015","journal-title":"Drugs Aging"},{"issue":"1","key":"2023103102463053400_ref40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13104-018-3260-6","article-title":"Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice","volume":"11","author":"Stark","year":"2018","journal-title":"BMC Res Notes"},{"issue":"1","key":"2023103102463053400_ref41","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2023103102463053400_ref42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Ovarian Res"},{"issue":"5","key":"2023103102463053400_ref43","first-page":"970","article-title":"Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2023103102463053400_ref44","first-page":"131","article-title":"Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer","volume":"10","author":"Franco","year":"2018","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"17","key":"2023103102463053400_ref45","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.3390\/cancers13174421","article-title":"Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023103102463053400_ref46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"issue":"1","key":"2023103102463053400_ref47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00001813-200501000-00003","article-title":"Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial","volume":"16","author":"Schmid","year":"2005","journal-title":"Anti-Cancer Drugs"}],"container-title":["Toxicology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/12\/5\/807\/52669300\/tfad072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/12\/5\/807\/52669300\/tfad072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:30:16Z","timestamp":1698733816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxres\/article\/12\/5\/807\/7252278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,26]]},"published-print":{"date-parts":[[2023,10,29]]}},"URL":"https:\/\/doi.org\/10.1093\/toxres\/tfad072","relation":{},"ISSN":["2045-4538"],"issn-type":[{"value":"2045-4538","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,26]]}}}